Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31448388 | 1.00 | HPGD (0.55) | HPGDLMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL3067646 | 0.88 | MAPT (0.43) | HPGDLMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL14070022 | 0.84 | LMNA (0.64) | HPGDLMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL2890802 | 0.79 | HPGD (0.59) | HPGDLMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL6212532 | 0.79 | ALDH1A1 (0.44) | HPGDLMNAALDH1A1KMT2APOLB | |
| SCHEMBL29955014 | 0.79 | HPGD (0.59) | HPGDLMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL5302174 | 0.77 | AHR (0.53) | HPGDALDH1A1KMT2ATDP1HSD17B10 | |
| SCHEMBL30787730 | 0.77 | AHR (0.53) | HPGDALDH1A1KMT2ATDP1HSD17B10 | |
| SCHEMBL19918087 | 0.76 | CYP3A4 (0.50) | HPGDLMNAALDH1A1KMT2APOLB | |
| SCHEMBL22133239 | 0.75 | LMNA (0.55) | HPGDLMNAALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143792-A1 | PIPERIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国药科大学 | 2021-07-22 | — | — | WO | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180273482-A1 | COMPOSITIONS AND METHODS FOR INCREASING, OR PREVENTING OR REVERSING LOSS OF, SKIN PIGMENTATION IN A MAMMALIAN SUBJECT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| EP-3280702-A1 | COMPOSITIONS AND METHODS FOR INCREASING, OR PREVENTING OR REVERSING LOSS OF, SKIN PIGMENTATION IN A MAMMALIAN SUBJECT | The Trustees Of The University Of Pennsylvania (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| WO-2016164450-A1 | COMPOSITIONS AND METHODS FOR INCREASING, OR PREVENTING OR REVERSING LOSS OF, SKIN PIGMENTATION IN A MAMMALIAN SUBJECT | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-10-13 | — | — | WO | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-5696301-A | Process for preparing protocatechualdehyde | UBE INDUSTRIES, LTD. (JP) | 1997-12-09 | — | — | US | disclosed |
| WO-1997043260-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0786446-A1 | Process for preparing protocatechualdehyde | UBE INDUSTRIES, LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
| WO-1997015570-A1 | NOVEL ACID PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR, USE THEREOF AS DRUGS, NOVEL USE THEREFOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH DERIVATIVES | HOECHST MARION ROUSSEL (FR) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996033190-A1 | QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THE RESULTANT INTERMEDIATES, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996012706-A1 | NOVEL ACID PYRAZOLE AND PYRAZOLONE DERIVATIVES FOR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ROUSSEL UCLAF (FR) | 1996-05-02 | — | — | WO | disclosed |
| EP-0285267-A2 | Pyridine derivatives for treatment and prevention of liver damage, and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-10-05 | — | — | EP | disclosed |
| US-4058607-A | DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES | AIRWICK INDUSTRIES, INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-3962415-A | Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer | AIRWICK INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | HPGD 1171/4885LMNA 3157/4885ALDH1A1 1326/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | HPGD 1171/4885LMNA 3157/4885ALDH1A1 1326/4885 |
| US-20180273482-A1 | COMPOSITIONS AND METHODS FOR INCREASING, OR PREVENTING OR REVERSING LOSS OF, SKIN PIGMENTATION IN A MAMMALIAN SUBJECT | GPER1, SHBG, ESRRB | HPGD 257/4885LMNA 1921/4885ALDH1A1 681/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | HPGD 1171/4885LMNA 3157/4885ALDH1A1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.